A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in
 subjects with type 2 diabetes.
Inclusion Criteria:

 -  Diagnosis of type 2 diabetes meeting all of the following:

 -  Minimum 6 month history of diabetes prior to screening visit;

 -  Fasting C-peptide ≥ 0.8 ng/mL at screening visit;

 -  HbA1C at screening visit 7-10%;

 -  Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose
 regulating drugs and supplements.

 -  BMI at screening visit from 25-35 kg/m2;

 -  LDL-C at screening ≥ 100 mg/dL